In addition, the in vivo antitumor activity of neutralizing anti-BAFF mAb in SCID-hu model of human MM provide the preclinical rationale for its evaluation in the treatment of MM [86]. The gene discussed is TNFSF13B; the disease is Miyoshi myopathy.